Article Text

PDF
New oral drugs for erectile dysfunction

Abstract

In 1998, we concluded that sildenafil (Viagra - Pfizer Ltd), a selective phosphodiesterase type 5 inhibitor, appeared to offer advantages over other medical approaches for erectile dysfunction in terms of ease of administration and cost.1 Oral drug treatment is now widely advocated as first-line therapy for erectile dysfunction,2 except where the cause is clearly psychological. In the past 4 years, three more oral preparations have been licensed in the UK for the treatment of men with erectile dysfunction. A sublingual preparation of the dopaminergic agonist ▼apomorphine (Uprima - Abbott Laboratories Ltd) is the first centrally acting drug to be licensed. ▼Tadalafil (Cialis - Eli-Lilly) and ▼vardenafil (Levitra - Bayer PLC) are phosphodiesterase type 5 inhibitors. Here we review the place of these preparations for men with erectile dysfunction.

Statistics from Altmetric.com

  • Relevant BNF section: 7.4.5

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.